Table 5.
Univariate and multivariate survival analyses of the prognostic factors for overall and disease-free survival in EOC patients.
| Variable | Cases (N) | Progression-free survival | Overall survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||
| Media of PFS | Pa | HR | 95% CI for HR | Pb | Media of OS | Pa | HR | 95% CI for HR | Pb | ||
| Age (years) | 0.532 | NA | NA | NA | 0.147 | NA | NA | NA | |||
| ≤52 | 62 | 6 | 17 | ||||||||
| >52 | 62 | 4 | 13 | ||||||||
| Menopause | 0.042 | 0.686 | 0.467–1.006 | 0.054 | 0.725 | NA | NA | NA | |||
| Yes | 76 | 4 | 15 | ||||||||
| No | 48 | 6 | 13 | ||||||||
| Pathologic type | 0.088 | NA | NA | NA | 0.777 | NA | NA | NA | |||
| Serous | 82 | 4 | 15 | ||||||||
| Mucous and others | 42 | 6 | 15 | ||||||||
| Histologic grade | 0.012 | 1.015 | 0.651–1.583 | 0.947 | 0.017 | 1.208 | 0.716–2.037 | 0.479 | |||
| G1−2 | 47 | 6 | 17 | ||||||||
| G3 | 77 | 5 | 13 | ||||||||
| FIGO Stage | 0.001 | 0.829 | 0.487–1.409 | 0.488 | <0.001 | 0.560 | 0.319–0.984 | 0.044 | |||
| I–II | 51 | 6 | 20 | ||||||||
| III–IV | 73 | 4 | 13 | ||||||||
| LN metastasis | <0.001 | 0.523 | 0.328–0.836 | 0.007 | <0.001 | 0.645 | 0.385–1.081 | 0.096 | |||
| No | 76 | 6 | 18 | ||||||||
| Yes | 48 | 3 | 12 | ||||||||
| Residual tumor | 0.041 | 1.349 | 0.862–2.112 | 0.190 | 0.001 | 1.447 | 0.875–2.393 | 0.150 | |||
| <1 cm | 93 | 6 | 18 | ||||||||
| ≥1 cm | 31 | 4 | 12 | ||||||||
| Ascites volume (ml) | 0.576 | NA | NA | NA | 0.608 | NA | NA | NA | |||
| ≤2,000 | 103 | 15 | |||||||||
| >2,000 | 21 | 14 | |||||||||
| Serum CA125 (U/ml) | 0.374 | NA | NA | NA | 0.070 | NA | NA | NA | |||
| ≤573.35 | 74 | 6 | 17 | ||||||||
| >573.35 | 50 | 5 | 13 | ||||||||
| VEGF expression | 0.049 | 1.396 | 0.864–2.255 | 0.172 | 0.036 | 1.208 | 0.733–1.990 | 0.458 | |||
| Negative | 73 | 6 | 17 | ||||||||
| Positive | 51 | 5 | 13 | ||||||||
| SEMA4D expression | 0.003 | 1.448 | 0.937–2.238 | 0.096 | <0.001 | 2.561 | 1.493–4.392 | 0.001 | |||
| Negative | 49 | 6 | 19 | ||||||||
| Positive | 75 | 5 | 13 | ||||||||
| PD-L1 expression | 0.025 | 0.834 | 0.517–1.344 | 0.455 | 0.047 | 0.942 | 0.579–1.534 | 0.811 | |||
| Negative | 63 | 6 | 18 | ||||||||
| Positive | 61 | 13 | |||||||||
| Patients' response to BC | 4 | 0.040 | 0.528 | 0.350–0.799 | 0.002 | 0.014 | 0.409 | 0.263–0.636 | <0.001 | ||
| Response (CR, PR and SD) | 63 | 6 | 16 | ||||||||
| Non-response (PD) | 61 | 4 | 13 | ||||||||
Pa, P value, log rank test; HR, hazard ratio; CI, confidence interval; Pb, P value, Cox regression; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable; BC, bevacizumab plus single regimen chemotherapy.